Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,847
datasets available to search
ShareScore release 0.9.0
Dataset results
1,847 results for “psoriasis”
Preprocessed and Harmonised Transcriptomics Datasets for Psoriasis and Atopic Dermatitis
<p>The datasets uploaded within this record contain transcriptomics data of psoriasis and atopic dermatitis patients retrieved from the NCBI Gene Expression Omnibus and EBI ArrayExpress repositories. Overall, we retrieved 39 transcriptomics datasets, produced through both DNA microarrays and RNA-Sequencing technologies, along with relative meta-data tables. After data collection, each dataset was quality checked and preprocessed in order to obtain a harmonised source of data, ready-to-use for the research community. Beside, a thorough quality check was carried out on the retrieved meta-data, and data dictionaries were created (both for DNA microarry and RNA-Seq datasets) in order to homogenise the phenotypic data, enabling the comparability across the datasets. </p>
Psoriasis is associated with elevated gut IL-1α and intestinal microbiome alterations
<p>Background: Psoriasis is a chronic inflammatory condition that predominantly affects the skin and is associated with extracutaneous disorders, such as inflammatory bowel disease and arthritis. Changes in gut immunology and microbiota are important drivers of proinflammatory disorders and could play a role in the pathogenesis of psoriasis. Therefore, we explored whether psoriasis in a Central Asian cohort is associated with alterations in select immunological markers and/or microbiota of the gut. Methods: We undertook a case-control study of stool samples collected from outpatients, aged 30-45 years, of a dermatology clinic in Kazakhstan presenting with plaque, guttate or palmoplantar psoriasis (n=20), and age-sex matched subjects without psoriasis (n=20). Stool supernatant was subjected to multiplex ELISA to assess the concentration of 47 cytokines and immunoglobulins and to 16S rRNA gene sequencing to characterize microbial diversity in both psoriasis participants and controls. Results: The psoriasis group tended to have higher concentrations of most analytes in stool (29/47=61.7%) and gut IL-1α was significantly elevated (4.19-fold, p=0.007) compared to controls. Levels of gut IL-1α in the psoriasis participants remained significantly unaltered up to three months after the first sampling (p=0.430). Psoriasis was associated with alterations in gut Firmicutes, including elevated Faecalibacterium and decreased Oscillibacter and Roseburia abundance, but no association was observed between gut microbial diversity or Firmicutes/Bacteroidetes ratios and disease status.<br> Conclusions: Psoriasis may be associated with gut inflammation and dysbiosis. Studies are warranted to explore the use of gut microbiome-focused therapies in the management of psoriasis in this under-studied population.</p>
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT03020199. IPD Sharing: YES. Countries: 13. Publications: 0.
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT03504852. IPD Sharing: YES. Countries: 7. Publications: 1.
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
ClinicalTrials.gov study NCT02826603. IPD Sharing: UNDECIDED. Countries: 11. Publications: 4.
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
ClinicalTrials.gov study NCT03055494. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
ClinicalTrials.gov study NCT01544595. IPD Sharing: UNDECIDED. Countries: 26. Publications: 1.
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
ClinicalTrials.gov study NCT02471144. IPD Sharing: YES. Countries: 19. Publications: 2.
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
ClinicalTrials.gov study NCT02074982. IPD Sharing: UNDECIDED. Countries: 24. Publications: 5.
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT04999839. IPD Sharing: YES. Countries: 2. Publications: 1.
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT03668613. IPD Sharing: YES. Countries: 9. Publications: 4.
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT02690701. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
ClinicalTrials.gov study NCT03066609. IPD Sharing: UNDECIDED. Countries: 6. Publications: 1.
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
ClinicalTrials.gov study NCT01636687. IPD Sharing: UNDECIDED. Countries: 5. Publications: 6.
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
ClinicalTrials.gov study NCT02752776. IPD Sharing: YES. Countries: 17. Publications: 2.
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
ClinicalTrials.gov study NCT01640951. IPD Sharing: UNDECIDED. Countries: 15. Publications: 1.
Psoriatic arthritis disease subtypes are phenocopied in a novel humanized murine model of psoriasis and joint inflammation
<p><em><span>Data processing and analysis</span></em></p> <p><span>Data normalization, quality control, and analysis was conducted by the UPMC Hillman Cancer Bioinformatics Services. Following the GeoMX NGS pipeline (<span>sequencing saturation 92%±0.12% (mean±S.E.M)), t</span>he resulting read count matrix was passed through robust QC procedure to remove ROIs of low surface area (<5000 µm<sup>2</sup>) or low perfect aligned reads (<80%), and probes of low quality or identified as global or local outliers (fails Grubbs outlier test in ≥ 20% segments). The remaining data were back-ground subtracted and Q3 normalized to house-keeping genes. ROIs were considered positive for CD8 T cells if their CD8 memory T cell deconvolution fraction was > 0 (R, spatialDecon, CellProfileLibrary; Human Adult ImmuneTumor_safeTME profile). Genes differentially expressed between groups of interest were detected using gene-wise linear modeling in R (edgeR, limma v3.50.3), with p-value adjusted for false discovery rate. Contrasts of groups were performed using t-tests at a significance level of 0.05.</span></p>
Keratinocytes derived from patient-specific iPSCs recapitulate the genetic signature of psoriasis disease
<p>Induced pluripotent stem cells (iPSCs) were generated from control (Ctrl) and two psoriasis patients (PsO1 and PsO2) having genetic background of psoriasis. The iPSCs were differentiated into epidermal keratinocytes as described in the article entitled "Keratinocytes derived from patient-specific iPSCs recapitulate the genetic signature of psoriasis disease" by Gowher et al. The dataset represent RNA-seq data generated from keratiocytes derived from ctrl-iPSCs and psoriasis patients iPSCs (PsO1 and PsO2).</p> <p>The file name is : Sample name with replicate_overall sample number_read direction_001 where:</p> <p>- Ctrl Rep1 and Ctrl Rep2: Keratinocytes derived from control (Ctrl-iPSCs). </p> <p>- PSO1 Rep1 and PSO1 Rep2: Keratinocytes derived from psoriasis patient iPSCs (PSO1-iPSCs)</p> <p>- PSO2 Rep1 and PSO2 Rep2: Keratinocytes derived from psoriasis patient iPSCs (PSO2-iPSCs).</p> <p>- RNA-seq data was generated from two biological repliicates (Rep1 and Rep2).</p> <p>- Read direction: R1 (Forward), R2 (Reverse).</p> <p> </p>
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
ClinicalTrials.gov study NCT03930186. IPD Sharing: YES. Countries: 2. Publications: 2.
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
ClinicalTrials.gov study NCT04211363. IPD Sharing: NO. Countries: 2. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.